Trial Profile
Efficacy and safety of lanreotide in Japanese patients with acromegaly or pituitary gigantism
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly; Gigantism
- Focus Adverse reactions; Therapeutic Use
- Sponsors Teijin Pharma
- 30 Mar 2015 New trial record